Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense anticancer oligonucleotide therapeutics.

H Wang1, G Prasad, J K Buolamwini

  • 1Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Cancer Pharmacology Laboratory, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Current Cancer Drug Targets
|August 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxicity Assessment and Plasma Vitellogenin Expression in Nile Tilapia (Oreochromis niloticus) Exposed to an Endocrine Disruptor, Triclosan.

Journal of applied toxicology : JAT·2026
Same author

Oxidative Stress Biomarkers and Antioxidant Enzymes in Liver and White Muscle of Nile Tilapia, Oreochromis niloticus, Exposed to an Endocrine Disruptor, Triclosan.

Journal of applied toxicology : JAT·2025
Same author

Electroencephalography and psychological assessment datasets to determine the efficacy of a low-cost, wearable neurotechnology intervention for reducing Post-Traumatic Stress Disorder symptom severity.

Data in brief·2022
Same author

On the taxonomy and distribution of the orb-weaving spider Philoponella feroka (Bradoo, 1979) n. comb. from India (Araneae, Uloboridae).

Zootaxa·2022
Same author

Neurofeedback with low-cost, wearable electroencephalography (EEG) reduces symptoms in chronic Post-Traumatic Stress Disorder.

Journal of affective disorders·2021
Same author

The significance of urgent ultrasound scan for shoulder dislocation in patients above the age of 40: A prospective British Elbow and Shoulder Society pathway implementation study.

Shoulder & elbow·2021

Antisense therapy, a genetic treatment, uses antisense oligonucleotides to block disease-causing genes. This review covers its development from lab to clinic, highlighting its promise for cancer treatment.

Area of Science:

  • Molecular Biology
  • Biotechnology
  • Genetics
  • Genetic Therapy

Background:

  • Advances in gene identification and characterization have enabled genetic therapies.
  • Antisense therapy utilizes antisense oligonucleotides to inhibit pathogenic gene expression by targeting mRNA.
  • This approach offers specific, rational, and genetic-based therapeutic strategies.

Purpose of the Study:

  • To review the development of antisense therapy from preclinical to clinical stages.
  • To highlight the progress and potential of antisense oligonucleotides as therapeutic agents.
  • To discuss key considerations in developing antisense drugs, including target selection and chemistry.

Main Methods:

  • Review of preclinical and clinical studies on antisense oligonucleotides.

Related Experiment Videos

  • Examination of specific cancer targets (e.g., bcl-2, BCR-ABL, p53) for antisense therapy.
  • Discussion of advanced antisense chemistry and drug development approaches.
  • Main Results:

    • Significant progress in antisense therapy development over the past decade.
    • Approval of the first antisense drug for clinical use.
    • Demonstrated potential of antisense oligonucleotides in targeting various cancer-related genes.

    Conclusions:

    • Antisense therapy represents a promising frontier in genetic-based therapeutics.
    • Effective target selection and advanced chemistry are crucial for successful antisense drug development.
    • The field shows considerable potential, particularly for human cancer therapy.